Leonid Timashev
Stock Analyst at RBC Capital
(1.00)
# 3,584
Out of 4,829 analysts
75
Total ratings
27.94%
Success rate
-16.28%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $82 → $80 | $31.70 | +152.41% | 3 | May 7, 2025 | |
| ALKS Alkermes | Maintains: Sector Perform | $39 → $40 | $30.13 | +32.76% | 2 | May 2, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $190 → $193 | $107.76 | +79.10% | 9 | Apr 29, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $56 → $52 | $14.58 | +256.65% | 11 | Apr 3, 2025 | |
| PYXS Pyxis Oncology | Reiterates: Outperform | $8 | $1.07 | +647.66% | 6 | Mar 19, 2025 | |
| BRCC BRC Inc. | Maintains: Buy | $3 | $1.63 | +84.05% | 1 | Mar 19, 2025 | |
| INSM Insmed | Reiterates: Outperform | $100 | $65.08 | +53.66% | 2 | Mar 19, 2025 | |
| BHVN Biohaven | Reiterates: Outperform | $61 | $20.24 | +201.38% | 10 | Mar 4, 2025 | |
| NAMS NewAmsterdam Pharma Company | Reiterates: Outperform | $40 | $18.37 | +117.75% | 6 | Jan 24, 2025 | |
| INCY Incyte | Reiterates: Sector Perform | $70 | $58.98 | +18.68% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $18 | $3.79 | +374.93% | 4 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $86 | $31.78 | +170.61% | 12 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $3.50 | +14.29% | 8 | Aug 6, 2024 |
Cytokinetics
May 7, 2025
Maintains: Outperform
Price Target: $82 → $80
Current: $31.70
Upside: +152.41%
Alkermes
May 2, 2025
Maintains: Sector Perform
Price Target: $39 → $40
Current: $30.13
Upside: +32.76%
Axsome Therapeutics
Apr 29, 2025
Maintains: Outperform
Price Target: $190 → $193
Current: $107.76
Upside: +79.10%
Edgewise Therapeutics
Apr 3, 2025
Maintains: Outperform
Price Target: $56 → $52
Current: $14.58
Upside: +256.65%
Pyxis Oncology
Mar 19, 2025
Reiterates: Outperform
Price Target: $8
Current: $1.07
Upside: +647.66%
BRC Inc.
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $1.63
Upside: +84.05%
Insmed
Mar 19, 2025
Reiterates: Outperform
Price Target: $100
Current: $65.08
Upside: +53.66%
Biohaven
Mar 4, 2025
Reiterates: Outperform
Price Target: $61
Current: $20.24
Upside: +201.38%
NewAmsterdam Pharma Company
Jan 24, 2025
Reiterates: Outperform
Price Target: $40
Current: $18.37
Upside: +117.75%
Incyte
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $58.98
Upside: +18.68%
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $3.79
Upside: +374.93%
Dec 9, 2024
Reiterates: Outperform
Price Target: $86
Current: $31.78
Upside: +170.61%
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $3.50
Upside: +14.29%